Reports related to this article:
Project(s): View 5 related projects in PECWeb
Plant(s): View 4 related plants in PECWeb
Released January 17, 2017 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--When many people hear the word "Texas," it evokes a number of clichés, typically a mélange of cattle, chemical plants, oil and gas drilling, and rodeos. But that sells the state short, for beyond the smoke stacks of the hundreds of the state's chemical processing plants and refineries are a surprising number of life-science manufacturing plants and research centers.
Click on the image at right for a graph detailing the top 10 counties for pharma-biotech projects in Texas.
A recent survey taken from Industrial Info's PECWEB Direct revealed 91 active projects, with a cumulative investment value of $4 billion, in various stages of development. Some are under construction, while others are in preliminary planning. Of this total, almost exactly half (45 projects worth $1.85 billion) have a future kick-off date.
These projects top every city planner's list because of the typically high wages and future expansion prospects they offer. The Houston area is slowly building on its commercial life-science potential. As home to the world's top medical center, the area is a veritable brain trust when it comes to answering the medical needs of human beings.
While not yet a threat to traditional pharmaceutical-biotech hubs on the east and west coasts, the state is actively wooing the industry. To erase the preconceived notion of Texas as only a location for heavy process industry, and not a good match for the "clean" manufacturing and research of pharmaceutical and biotech companies. That is a fallacy.
According to a May 2016 report from industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical industry in Texas pays $103,807 average per employee in direct jobs with the sector, as opposed to the $59,839 average per employee in all Texas jobs. The biopharmaceutical sector directly accounted for 36,485 jobs in Texas in 2014, and supported another 157,551 jobs in Texas for a total of 194,036 jobs. These additional jobs were with vendors and suppliers to the biopharmaceutical sector and with businesses that serve its employees, in sectors ranging from transportation and construction to health care and IT.
What Texas has to offer is a lot of empty space and a pro-business environment. The intellectual capital is present and accounted for, as well as a plethora of able workers. It is going to take more effort to overcome the clichés, but there are signs the tide is slowly turning. Supporting the commercial growth plan, the educational sector is delivering advanced research facilities throughout the state.
While $10 million is not large when it comes to typical pharmaceutical-biotech project, when it is sourced out of industry giant Johnson & Johnson (NYSE:JNJ) (J&J) (New Brunswick, New Jersey) and located in Houston's Texas Medical Center (TMCx), it becomes major news. The current $10 million project will build the Center for Device Innovation at Texas Medical Center (TMC). Located on the McGovern Campus, the project will construct and equip approximately 26,000 square feet to house medical device research. For more information, see Industrial Info's project report.
This follows J&J's 2015 investment to renovate and upfit approximately 30,000 square feet within the TMC's 100,000-square-foot Innovation Institute, known as the J-Labs, it offers laboratory and innovation services for up to 50 start-up/nascent biotechnology and other life science companies. For more information, see Industrial Info's project report.
Allergan plc (NYSE:AGN) (Dublin, Ireland) tapped its Waco campus at the site for a $200 million expansion. To the existing 400,000-square-foot facility, the project will add approximately 322,000 square feet (including a 221,000-square-foot first floor expansion and an approximately 87,000-square-foot mezzanine level expansion), along with added warehouse space. Upon completion, the company will have double the current production capacity of ophthalmic and dermatological gels, suspensions, solutions, ointments and other related pharmaceuticals (products include, Restasis, Lumigan, Combigan, Refresh Plus, Refresh Tears and Latisse). For more information, see Industrial Info's project report.
In Pearland, Lonza Group (Basel, Switzerland) decided to invest $150 million on a new plant to house viral and immunotherapy development and manufacturing. When complete, the site will offer process development, quality-control laboratories and a fully segregated fill/finish suite, essentially doubling the company's current capacity for the production of viral gene and virally modified therapeutics. The facility's eight modular cleanrooms will allow for up to 2,000 L-scale production in single-use bioreactors, along with cleanrooms designed to meet the requirements for the manufacture of cell therapy products for use in both the U.S. and European markets. For more information, see Industrial Info's project report.
Novartis' (NYSE:NVS) (Basel, Switzerland) Alcon division is building a $100 million addition to its Ophthalmic Solutions sterile products facility in Fort Worth, Texas. A new sterile filling and packaging building would be added on the 100-acre Alcon campus, to support the existing 72,000-square-foot facility. Current production capacity is approximately 12 million to 16 million units per month of aseptic eye and ear solutions. For more information, see Industrial Info's project report.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
Click on the image at right for a graph detailing the top 10 counties for pharma-biotech projects in Texas.A recent survey taken from Industrial Info's PECWEB Direct revealed 91 active projects, with a cumulative investment value of $4 billion, in various stages of development. Some are under construction, while others are in preliminary planning. Of this total, almost exactly half (45 projects worth $1.85 billion) have a future kick-off date.
These projects top every city planner's list because of the typically high wages and future expansion prospects they offer. The Houston area is slowly building on its commercial life-science potential. As home to the world's top medical center, the area is a veritable brain trust when it comes to answering the medical needs of human beings.
While not yet a threat to traditional pharmaceutical-biotech hubs on the east and west coasts, the state is actively wooing the industry. To erase the preconceived notion of Texas as only a location for heavy process industry, and not a good match for the "clean" manufacturing and research of pharmaceutical and biotech companies. That is a fallacy.
According to a May 2016 report from industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical industry in Texas pays $103,807 average per employee in direct jobs with the sector, as opposed to the $59,839 average per employee in all Texas jobs. The biopharmaceutical sector directly accounted for 36,485 jobs in Texas in 2014, and supported another 157,551 jobs in Texas for a total of 194,036 jobs. These additional jobs were with vendors and suppliers to the biopharmaceutical sector and with businesses that serve its employees, in sectors ranging from transportation and construction to health care and IT.
What Texas has to offer is a lot of empty space and a pro-business environment. The intellectual capital is present and accounted for, as well as a plethora of able workers. It is going to take more effort to overcome the clichés, but there are signs the tide is slowly turning. Supporting the commercial growth plan, the educational sector is delivering advanced research facilities throughout the state.
While $10 million is not large when it comes to typical pharmaceutical-biotech project, when it is sourced out of industry giant Johnson & Johnson (NYSE:JNJ) (J&J) (New Brunswick, New Jersey) and located in Houston's Texas Medical Center (TMCx), it becomes major news. The current $10 million project will build the Center for Device Innovation at Texas Medical Center (TMC). Located on the McGovern Campus, the project will construct and equip approximately 26,000 square feet to house medical device research. For more information, see Industrial Info's project report.
This follows J&J's 2015 investment to renovate and upfit approximately 30,000 square feet within the TMC's 100,000-square-foot Innovation Institute, known as the J-Labs, it offers laboratory and innovation services for up to 50 start-up/nascent biotechnology and other life science companies. For more information, see Industrial Info's project report.
Allergan plc (NYSE:AGN) (Dublin, Ireland) tapped its Waco campus at the site for a $200 million expansion. To the existing 400,000-square-foot facility, the project will add approximately 322,000 square feet (including a 221,000-square-foot first floor expansion and an approximately 87,000-square-foot mezzanine level expansion), along with added warehouse space. Upon completion, the company will have double the current production capacity of ophthalmic and dermatological gels, suspensions, solutions, ointments and other related pharmaceuticals (products include, Restasis, Lumigan, Combigan, Refresh Plus, Refresh Tears and Latisse). For more information, see Industrial Info's project report.
In Pearland, Lonza Group (Basel, Switzerland) decided to invest $150 million on a new plant to house viral and immunotherapy development and manufacturing. When complete, the site will offer process development, quality-control laboratories and a fully segregated fill/finish suite, essentially doubling the company's current capacity for the production of viral gene and virally modified therapeutics. The facility's eight modular cleanrooms will allow for up to 2,000 L-scale production in single-use bioreactors, along with cleanrooms designed to meet the requirements for the manufacture of cell therapy products for use in both the U.S. and European markets. For more information, see Industrial Info's project report.
Novartis' (NYSE:NVS) (Basel, Switzerland) Alcon division is building a $100 million addition to its Ophthalmic Solutions sterile products facility in Fort Worth, Texas. A new sterile filling and packaging building would be added on the 100-acre Alcon campus, to support the existing 72,000-square-foot facility. Current production capacity is approximately 12 million to 16 million units per month of aseptic eye and ear solutions. For more information, see Industrial Info's project report.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
